Yarrow Bioscience, Inc. (YARW)
NASDAQ: YARW · Real-Time Price · USD
41.52
+0.12 (0.29%)
At close: Aug 18, 2026, 4:00 PM EDT
41.52
0.00 (0.00%)
After-hours: Aug 18, 2026, 4:10 PM EDT
Company Description
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
The company’s candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease and thyroid eye disease.
The company was incorporated in 2025 and is based in New York, New York.
Yarrow Bioscience, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Rebecca Velez Frey |
Contact Details
Address: 40 10 th Avenue, Floor 7 New York, New York 10014 United States | |
| Website | yarrowbioscience.com |
Stock Details
| Ticker Symbol | YARW |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1566044 |
| CUSIP Number | 92941V407 |
| ISIN Number | US92941V4077 |
| Employer ID | 45-3757789 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rebecca Velez Frey Pharm.D. | President, Chief Executive Officer and Director |
| Rachael Alford Ph.D. | Chief Operating Officer |
| Dr. Lori Payton Ph.D. | Chief Development Officer |
| Dr. Steven W. Ryder F.A.C.P, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 13, 2026 | 8-K/A | [Amend] Current report |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | SCHEDULE 13G/A | Filing |
| Aug 7, 2026 | SCHEDULE 13G/A | Filing |
| Aug 7, 2026 | SCHEDULE 13G | Filing |
| Aug 5, 2026 | SCHEDULE 13D | Filing |
| Aug 4, 2026 | SCHEDULE 13G | Filing |